Company intelligence / Profile preview

Green Fountain

South San Francisco, California, United Statesfountaintx.com ↗

Ownership: Private
Development stage: Other

Overview

Fountain Therapeutics develops first-in-class therapies for diseases caused by aging, using an AI-powered cell-based drug discovery platform. Its lead small molecule program aims to prevent or reverse muscle and lean tissue loss associated with aging or GLP agonist use. The company has raised over $26 million in Series A funding from top-tier investors including Eli Lilly, Khosla Ventures, Nan Fung Life Sciences, Alexandria Venture Investments, and R42 Group. No clinical results have been published yet; programs remain preclinical.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Green Fountain.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Green Fountain.